Navigation Links
MedImmune To Present Seven Posters On Influenza, Respiratory Syncytial Virus At The Annual Pediatric Academic Societies Meeting
Date:5/4/2013

GAITHERSBURG, Md., May 4, 2013 /PRNewswire/ -- MedImmune announced today it will conduct seven poster and/or presentations at the Pediatric Academic Societies (PAS) Meeting at the Walter E. Washington Convention Center in Washington DC, May 4-7, 2013.  These abstracts advance the body of existing data and knowledge around influenza and respiratory syncytial virus (RSV) prevention, highlighting MedImmune's continued commitment to patient health.

MedImmune posters to be presented at PAS regarding influenza include:

  • Efficacy of Live Attenuated Influenza Vaccine Against Moderate to Severe Versus Mild Influenza Illness in Children. Ambrose CS, Wu X, Belshe RB. Platform Presentation Session: May 4, 2013, 9:45 AM, Session: Section 115- Infectious Diseases, Vaccines & Infections 

  • Serum HAI Antibody Response to LAIV in 2 to 49 Year Olds.Coelingh K, Wu X, Mallory R, Ambrose CS. Poster Session: May 4, 2013, 1:00 PM – 4:00 PM; Exhibit Hall D/E; Board: 493

MedImmune posters to be presented at PAS regarding RSV include:

  • Burden of and Risk Factors for Medically Attended RSV Illness in 32−35 w/GA Infants Not Receiving RSV Prophylaxis. Groothuis J, Wu X, Makari D, Ambrose CS.  Poster Session: May 4, 2013, 1:00 pm− 4:00 pm, Publication Number: 1500.4. Session: 1500 – Epidemiology, Exhibit Hall D/E, Board: 4

  • Risk for Medically Attended RSV Illness in 32−34 Weeks vs. 35 Weeks Gestational Age Preterm Infants Not Receiving Palivizumab.  Groothuis J, Wu X, Makari D, Ambrose CS.  Publication Number 1500.3.  Poster Session: May 4, 2013, 1:00 pm− 4:00 pm. Session: 1500 – Epidemiology, Exhibit Hall D/E, Board: 3 

  • Respiratory Syncytial Virus Surveillance, 2007–2012: Results from RSVAlert®, a U.S. National Hospital-Based Surveillance Program. Boron M, Kumar V, McGuiness CB, Saunders B, Rabon-Stith K .  Poster Session: May 4, 2013, 1:00 pm− 4:00 pm, Publication Number: 1500.7, Session: 1500 – Epidemiology, Exhibit Hall D/E, Board: 7

  • Impact of Partial Prophylaxis with Palivizumab on RSV Hospitalizations among Commercially-Insured High-Risk Preterm Infants. Ryan K, Stewart D, Frogel M, Becker L, Pinsky B. Poster Session : May 5, 2013, 4:15 pm− 7:30 pm. Publication Number: 2915.209. Session: 2915 − Infectious Diseases, Exhibit Hall D/E, Board: 209

  • Pharmacokinetic (PK) Profile of Palivizumab (Pali) in Premature Infants. La Via WV, Makari D, Yu X, Robbie GJ. Poster Session: May 7, 2013, 10:00 am− 2:00 pm. Publication Number: 4514.228.  Session: 4514 − Neonatal Infectious Diseases / Immunology, Exhibit Hall D/E, Board: 228

Additional information about the 2013 PAS conference can be found at
http://www.pas-meeting.org/2013DC/default.asp 

About MedImmune 
MedImmune is the worldwide biologics research and development arm of AstraZeneca, a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialization of small molecule and biologic prescription medicines.  MedImmune is pioneering innovative research and exploring novel pathways across key therapeutic areas, including respiratory, inflammation and autoimmunity; cardiovascular and metabolic disease; oncology; neuroscience; and infection and vaccines.  MedImmune has approximately 2,500 employees globally, with its headquarters located in Gaithersburg, Md., one of AstraZeneca's three global R&D centers.  For more information, please visit www.medimmune.com.


'/>"/>
SOURCE MedImmune
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. MedImmune and WuXi AppTec Announce Joint Venture to Develop Novel Biologic for Chinese Market
2. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
3. Boston Scientific Schedule of Major Events and Presentations at Heart Rhythm 2013
4. Heska Corporation to Present at the Bank of America Merrill Lynch 2013 Health Care Conference
5. Zimmer Holdings to Present at Deutsche Bank Securities Annual Health Care Conference
6. Janssen and Johnson & Johnson to Provide Webcast Presentation of Simeprevir Phase 3 Clinical Data Presented at The International Liver Congress of the European Association for the Study of the Liver (EASL)
7. Ferring Announces It Will Present Phase 3 Data for Cervical Ripening Agent at American College of Obstetricians and Gynecologists Annual Clinical Meeting
8. AcelRx Pharmaceuticals Presents Positive Clinical Data for the Sufentanil NanoTab PCA System at ASRA Medical Meeting
9. XBiotech to Present at UBS Global Healthcare Conference
10. Leonhardt Ventures to Present Technology Showcase @ Heart Rhythm 2013
11. Vatsala Naageshwaran of Absorption Systems to Present at Disso 2013 International Conference in Mumbai, India on May 3rd
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... 2017 Cardiology devices segment is anticipated to reach ... The Cardiology Devices segment is likely to create absolute $ ... 2018 over 2017. By the end of 2027, Cardiology Devices ... US$ 700 Mn, expanding at a CAGR of 18.4% over ... Asia Pacific reprocessed medical devices market in ...
(Date:4/19/2017)... , Tenn. and DALLAS , April ... EndoStim, Inc., announced that the first patients in ... the EndoStim device in the Lower Esophageal Sphincter Stimulation ... a minimally-invasive implantable device designed to provide long-term reflux ... neurostimulation. GERD affects nearly 65 million people ...
(Date:4/19/2017)... , April 19, 2017  Novartis today announced ... National Heart, Lung, and Blood Institute (NHLBI) of ... 58% of patients with treatment-naïve severe aplastic anemia ... treated with eltrombopag at the initiation of and ... study evaluated three sequential treatment groups, or cohorts. ...
Breaking Medicine Technology:
(Date:4/26/2017)... ... April 26, 2017 , ... ... the adoption of e-prescribing as measured in Part D Medicare data. The dataset, ... to pharmacies, either using e-prescribing, faxes or paper. The PaPR (pronounced "paper") ...
(Date:4/26/2017)... ... 2017 , ... Infertility may be a result of an ... many women become pregnant upon treating their diagnosis. , To properly ... We can provide the necessary information to diagnose and treat your problem. ...
(Date:4/26/2017)... ... 26, 2017 , ... New SUPRO® XT55 Isolated Soy ... by helping beverage manufacturers more effectively manage protein costs. “Soy protein has always ... well as more stable pricing over time. Now it’s even more relevant as ...
(Date:4/25/2017)... ... April 25, 2017 , ... Splashtop Inc. , ... . This new addition to the Mirroring360 product family combines device screen mirroring ... Mirroring360 Pro enables educators, business professionals and individuals to stream or mirror app ...
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... ... CEOs, CFOs and HR decision-makers are preparing for how his administration could impact ... will provide insight into what changes are most likely to make it through ...
Breaking Medicine News(10 mins):